Jing, Shan http://orcid.org/0000-0002-5648-111X
Lin, Yang http://orcid.org/0000-0002-3036-3633
Dockens, Randy
Marchisin, David
He, Bing
Girgis, Ihab G.
Chimalakonda, Anjaneya
Murthy, Bindu
Aras, Urvi
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pharmacokinetics and Safety of the Tyrosine KinaseĀ 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects
https://doi.org/10.1007/s13555-023-01050-7
Funding for this research was provided by:
Bristol-Myers Squibb
Article History
Received: 1 June 2023
Accepted: 25 September 2023
First Online: 19 November 2023
Declarations
:
: Shan Jing and Yang Lin declare that they have no competing interests. Randy Dockens, David Marchisin, Bing He, Bindu Murthy, and Urvi Aras declare that they are employees of and shareholders in Bristol Myers Squibb. Ihab G. Girgis and Anjaneya Chimalakonda declare that they were employees and shareholders in Bristol Myers Squibb at the time of study conduct; Ihab G. Girgis is now an employee of CSL Behring and Anjaneya Chimalakonda is now an employee of Boehringer Ingelheim.
: The study was conducted at a single clinical facility in China (Beijing Anzhen Hospital, Capital Medical University, Beijing, China) in accordance with the Declaration of Helsinki and the International Conference on Harmonization E6 Guidelines on Good Clinical Practice. An institutional review board reviewed and approved the study protocol and related documents, and all subjects provided written informed consent before any study procedures were performed.